Axsome Therapeutics (AXSM) Q3 Earnings Narrow Losses As Revenue Jumps

Axsome Therapeutics just released its Q3 2026 results and the headline is simple. The antidepressant specialist reported revenue of US$259.7m while reducing its net loss to US$12.9m. The stock had been under pressure in recent weeks, down 22% over the past month and 34% over three months, before moving 2.7% higher to US$139.61 after the release.

That modest bounce appears restrained when compared with the earnings report. This quarter is focused on one key theme: losses are narrowing as the commercial engine begins to catch up with Axsome Therapeutics’ spending.

Love Axsome Therapeutics’ surging revenue but concerned about ongoing losses and execution risk as the depression franchise scales up? Screen for biopharma peers with stronger balance sheets and cleaner income statements using our list of solid balance sheet and fundamentals stocks (24 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$259.7m vs. US$171.0m (up roughly 52% year on year)
• Net Loss (Q3 2026 vs. Q3 2025): US$12.9m loss vs. US$47.2m loss (loss narrowed materially year on year)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.25 loss per share vs. US$0.94 loss per share (per share loss reduced year on year)
• Gross Margin (Q3 2026): Low to mid 90% range in Q3 2026, indicating operating leverage as volumes scale

Axsome is pitching AUVELITY as an $8B-a-year drug. Ask Charlie what Axsome’s $8B AUVELITY goal really assumes.

Axsome Bull Case: Execution Targets Meet Hard Numbers

The bullish view hangs on Axsome Therapeutics turning a broad CNS portfolio into real prescription volume and a healthier P&L. One ambition is crystal clear.

"The main thing that has to go right is continued execution on Auvelity’s commercial rollout and broader CNS pipeline, including maintaining payer access, realizing operating leverage as SG&A plateaus, and successfully converting late-stage assets like AXS-12 into approved products."

Q3 results back up part of that script. Auvelity is now driving US$207.6m of the US$259.7m quarter, with prescriptions at 302,000 and strong coverage near 89%. SG&A of US$203.1m is essentially flat sequentially while net loss shrank to US$12.9m. AXS-12 remains on track with an accepted NDA and a May 1, 2027 PDUFA date.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Axsome Bear Case: SG&A Plateau Still Looks Pricey

Bears argue Axsome Therapeutics is spending ahead of proof that its broader CNS platform can really carry the weight.

"Although the Auvelity and SYMBRAVO sales forces have already been expanded and AI tools embedded across commercial workflows, SG&A reached about US$208m in Q2 2026 and is now expected only to plateau rather than fall. If the enlarged infrastructure and digital tools do not translate into the revenue lift implied in current models, earnings leverage could remain weaker than investors expect."

Q3 shows SG&A essentially flat at US$203.1m with revenue rising to US$259.7m and the net loss narrowing to US$12.9m. That supports early operating leverage. The miss is that management still offers no explicit profitability timeline or SG&A reduction milestones, so the durability of this efficiency remains unproven.

Hunt For Quiet Mispricings

Axsome Therapeutics just showed how sentiment can lag a changing income statement. The real opportunity could be spotting stocks that look mispriced before consensus adjusts.

• Company 1 - 48% below our estimate - uses a dense store rollout and app ordering to test whether expansion can offset softer same-store trends and rising rental and delivery costs.
• Company 2 - 43% below our estimate - scales larger video boards, software, and services as sports venues, transport projects, and youth leagues replace static signage with connected screens needing ongoing support contracts.
• Company 3 - 42% below our estimate - expands new manufacturing capacity and installer training so higher margin protective films and coatings become the default upgrade for vehicle and building refits.

Those are three of them. See the full list of 34 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com